State Street’s Royalty Pharma RPRX Stock Holding History

State Street’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$692M	Buy	12,338,229 +1,348,378	+12%	+$70.2M	0.02%	503
2026 Q1	$527M	Buy	10,989,851 +340,210	+3%	+$14.9M	0.02%	538
2025 Q4	$412M	Buy	10,649,641 +376,888	+4%	+$14.4M	0.01%	615
2025 Q3	$362M	Buy	10,272,753 +77,815	+0.8%	+$2.82M	0.01%	661
2025 Q2	$367M	Buy	10,194,938 +678,810	+7%	+$22.5M	0.01%	632
2025 Q1	$296M	Sell	9,516,128 -244,035	-3%	-$7.74M	0.01%	693
2024 Q4	$249M	Buy	9,760,163 +243,901	+3%	+$6.47M	0.01%	808
2024 Q3	$269M	Buy	9,516,262 +29,451	+0.3%	+$816K	0.01%	749
2024 Q2	$250M	Buy	9,486,811 +386,663	+4%	+$10.7M	0.01%	742
2024 Q1	$276M	Buy	9,100,148 +226,598	+3%	+$6.68M	0.01%	711
2023 Q4	$249M	Buy	8,873,550 +447,934	+5%	+$12.3M	0.01%	737
2023 Q3	$229M	Buy	8,425,616 +238,778	+3%	+$7.09M	0.01%	707
2023 Q2	$252M	Sell	8,186,838 -153,967	-2%	-$5.21M	0.01%	690
2023 Q1	$301M	Buy	8,340,805 +220,923	+3%	+$8.19M	0.02%	623
2022 Q4	$321M	Buy	8,119,882 +198,467	+3%	+$8.28M	0.02%	599
2022 Q3	$318M	Buy	7,921,415 +276,675	+4%	+$11.8M	0.02%	584
2022 Q2	$321M	Sell	7,644,740 -117,832	-2%	-$4.83M	0.02%	592
2022 Q1	$302M	Buy	7,762,572 +685,242	+10%	+$26.9M	0.02%	680
2021 Q4	$282M	Buy	7,077,330 +1,242,585	+21%	+$48.3M	0.01%	708
2021 Q3	$211M	Buy	5,834,745 +967,111	+20%	+$37.6M	0.01%	810
2021 Q2	$200M	Buy	4,867,634 +181,771	+4%	+$7.73M	0.01%	851
2021 Q1	$204M	Buy	4,685,863 +2,328,121	+99%	+$110M	0.01%	793
2020 Q4	$118M	Buy	2,357,742 +1,339,548	+132%	+$56.8M	0.01%	1024
2020 Q3	$42.8M	Buy	1,018,194 +977,394	+2,396%	+$41.9M	﹤0.01%	1573
2020 Q2	$1.98M	Buy	+40,800	New	+$2.02M	﹤0.01%	3182

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

State Street's RPRX Position: Q2 2026 in Review

State Street increased its Royalty Pharma (RPRX) stake by 12% in Q2 2026, buying an estimated $70.2M and bringing the position to 12,338,229 shares worth $692M. The position accounts for 0.02% of the portfolio, ranked #503.

State Street first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

State Street held 12,338,229 shares of Royalty Pharma worth $692M as of Q2 2026.
State Street bought 1,348,378 Royalty Pharma shares in Q2 2026, an estimated $70.2M.
Royalty Pharma made up 0.02% of State Street's portfolio in Q2 2026, its #503 holding.
State Street first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.